Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam
- PMID: 1506350
- DOI: 10.1093/jac/29.6.701
Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam
Abstract
The pharmacokinetics of cefoperazone 2 g combined with sulbactam 1 g after a single dose administered intravenously were evaluated in 24 subjects with normal and impaired renal function. Subjects were categorized into four groups based on endogenous creatinine clearance Clcr. Patients in groups 1, 2 and 3 had ClcrS of greater than 60, 31 to 60, and 10 to 30 mL/min/1.73 m2, respectively. Patients in group 4 required maintenance haemodialysis and were assumed to have Clcr less than 10 mL/min/1.73 m2. Pharmacokinetic parameters were determined by noncompartmental methods. No significant differences (P greater than 0.05) in mean peak serum cefoperazone-sulbactam concentrations for group 1 (208.4/29.0 mg/L), group 2 (199.0/34.1 mg/L), group 3 (163.2/35.0 mg/L), and group 4 (234.0/66.0 mg/L) were noted. Correlations between both total serum (r = 0.58) and renal (r = 0.35) clearance and creatinine clearances were negative for cefoperazone, although both were shown to decline with diminished renal function. Correlations between serum (r = 0.85) and renal (r = 0.72) clearances and creatinine clearance for sulbactam were, on the other hand, both positive and declined in a linear fashion. No significant differences in steady state volumes of distribution were noted for either cefoperazone (P = 0.53) or sulbactam (P = 0.85) amongst the four groups. After 24 h, urinary recovery was also comparable for both cefoperazone (P = 0.64) and sulbactam (P = 0.85) amongst the four groups. The concentrations of cefoperazone and sulbactam remained at or above the MICs (16/8 mg/L) for common bacterial pathogens for 2.5, 3, 7 and 14 h in groups 1, 2, 3 and 4, respectively.
Similar articles
-
Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.Antimicrob Agents Chemother. 1988 Apr;32(4):503-9. doi: 10.1128/AAC.32.4.503. Antimicrob Agents Chemother. 1988. PMID: 3377461 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.Antimicrob Agents Chemother. 1988 Jan;32(1):51-6. doi: 10.1128/AAC.32.1.51. Antimicrob Agents Chemother. 1988. PMID: 3348613 Free PMC article. Clinical Trial.
-
Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.Ann Pharmacother. 1994 Jun;28(6):703-7. doi: 10.1177/106002809402800602. Ann Pharmacother. 1994. PMID: 7919553
-
Sulbactam-containing beta-lactamase inhibitor combinations.Clin Microbiol Infect. 2008 Jan;14 Suppl 1:185-8. doi: 10.1111/j.1469-0691.2007.01847.x. Clin Microbiol Infect. 2008. PMID: 18154545 Review.
-
[Sulperazone--a combined form of cefoperazone with sulbactam].Antibiot Khimioter. 1995 Feb;40(2):55-70. Antibiot Khimioter. 1995. PMID: 7605145 Review. Russian. No abstract available.
Cited by
-
Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1777-1785. doi: 10.1007/s10096-024-04892-x. Epub 2024 Jul 12. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38995342 Free PMC article.
-
Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation.Antibiotics (Basel). 2023 Feb 9;12(2):363. doi: 10.3390/antibiotics12020363. Antibiotics (Basel). 2023. PMID: 36830273 Free PMC article.
-
Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia.Antibiotics (Basel). 2022 May 23;11(5):703. doi: 10.3390/antibiotics11050703. Antibiotics (Basel). 2022. PMID: 35625347 Free PMC article.
-
Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis.Pak J Med Sci. 2023 Jan-Feb;39(1):55-59. doi: 10.12669/pjms.39.1.6850. Pak J Med Sci. 2023. PMID: 36694775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical